ClinicalTrials.gg
RecruitingNCT07612280Updated Nov 17, 2026

Study to Assess Safety and Preliminary Efficacy of Orally Administered JBI-802 in Subjects With Essential Thrombocythemia (ET) and Polycythemia Vera (PV) With Thrombocytosis

A Phase 1/2 interventional study of JBI-802 in Essential Thrombocythemia (ET) and Polycythemia Vera, sponsored by Jubilant Therapeutics Inc.. Recruiting at 7 sites in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Jubilant Therapeutics Inc. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled Oct 2024, registered Aug 2025).
  • Started Oct 2024; still recruiting 2 years later.
Updated Nov 17, 2026Primary completion movedStudy completion moved+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
70
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 18 studies in Thrombocythemia, Essential with a site in Australia — 7 open to participants now, 10 under way, 4 of them phase 3. Thrombocythemia, Essential · Australia.

Planned enrollment
14th of 18
70 · median 140
Started
2024
with 2 others
Phase 1/2
3 of 18
1 open now
Registered
14th of 18
by date
Lead sponsor
1 of 18
Jubilant Therapeutics Inc.

Among the 18 studies in Thrombocythemia, Essential with a site in Australia, this one is the 14th largest by planned enrollment, is one of 3 that started in 2024, is one of 3 in phase 1/2, and was the 14th registered.

Thrombocythemia, Essential

229 studies on the registry are indexed under Thrombocythemia, Essential; 37 are open to participants now.

Browse Thrombocythemia, Essential studies →

Open to participants now

7 of the 18 studies in Thrombocythemia, Essential with a site in Australia are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 33 Thrombocythemia, Essential studies recruiting now, 29 (88%) set no upper age limit and 3 (9%) stop at 75 or younger; 5 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Thrombocythemia, Essential with a site in Australia, or all of them as a file.
02

Study summary

This Phase 1/2 study is evaluating the safety and preliminary effectiveness of JBI-802, an oral investigational medicine, in adults with essential thrombocythemia (ET) or polycythemia vera (PV) with thrombocytosis (high platelet counts).

The study has two parts. Part 1 evaluates different doses to select the recommended Phase 2 dose. The initial dose-escalation portion is complete, and additional participants may receive selected doses to further assess safety and activity. Part 2 will evaluate the selected dose in a larger group of participants with ET or PV.

JBI-802 is taken by mouth once daily in 28-day treatment cycles. Participants may continue treatment while they are benefiting, tolerating treatment, and meeting study requirements. Study assessments include medical examinations, laboratory tests, electrocardiograms, symptom assessments, bone marrow evaluations, and imaging when needed.

Read the detailed description

This is a multicenter, open-label Phase 1/2 study of oral JBI-802 in adults with ET or PV and thrombocytosis.

Part 1: Dose evaluation. The completed dose-escalation portion assessed increasing doses of JBI-802. Additional participants may receive selected doses to further evaluate safety, drug levels, biological effects, and preliminary clinical activity. The Safety Review Committee and Sponsor will use the available data to select the recommended Phase 2 dose.

Part 2: Dose expansion. After the recommended dose is selected, additional participants with ET or PV and thrombocytosis will receive that dose to further evaluate safety and clinical activity.

The study plans to enroll approximately 70 participants. Treatment may continue for up to 2 years, with a possible 12-month extension for participants who continue to benefit and meet protocol requirements.

03

Conditions studied

  • Essential Thrombocythemia (ET)
  • Polycythemia Vera
04

Who can participate

The criteria were revised on the registry on Nov 17, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18 years or older with ET or PV and persistent thrombocytosis ( count at least 450 × 10⁹/L).
  2. At least one recognized risk factor for thrombosis, such as prior thrombosis, age 60 years or older, or another investigator-determined risk factor.
  3. Disease that has not responded adequately to, or cannot tolerate, at least one standard cytoreductive therapy.
  4. Adequate blood counts, liver and kidney function, and coagulation results as defined in the protocol; performance status of 0 to 2.
  5. Able to swallow oral medication, provide , follow study requirements, and undergo required bone marrow assessments.
  6. Participants of must meet protocol requirements during treatment and for 90 days after the last dose.

Exclusion criteria

Exclusion Criteria:

  1. Recent anticancer, biological, kinase-inhibitor, , radiotherapy, major surgery, or other prohibited treatment without the required .
  2. Urgent need for plateletpheresis, recent hematopoietic cell transplant, active , or ongoing post-transplant .
  3. Severe or uncontrolled medical illness, heart disease or , active serious infection, active or or C infection, or a condition that may significantly affect drug absorption.
  4. Prohibited medicines or foods that strongly affect or CYP2D6 within the protocol-defined period.
  5. Pregnant or breastfeeding, planning pregnancy or fathering a child during the restricted period, or participating in another interventional study.
  6. Prior JBI-802 treatment, specified thrombocytopenic disorders, recent transfusion for thrombocytopenia, or cytoreductive therapy that has not been discontinued according to protocol washout requirements.
  7. Any other condition that, in the investigator's judgment, could create unacceptable risk or prevent full participation.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
70 participants (estimated)

Study arms

  • Experimental
    Dose Escalation: Escalating oral dose of JBI-802

    JBI-802 - CoREST inhibitor (Dual LSD1 and HDAC6 inhibitor)

    Drug: JBI-802

  • Experimental
    Dose Expansion: Expansion arm at the RP2D of oral JBI-802

    Drug: JBI-802

Interventions

  • CoREST inhibitor dual targeting LSD1 and HDAC6

06

What researchers measure

Primary outcomes

  1. Dose Escalation - Incidence of Dose-Limiting Toxicities (DLTs)

    Part 1: Number of participants with dose-limiting toxicity (DLT) events during the first 28-day treatment cycle Units: Number of participants

    Time frame: At the end of Cycle 1 (each cycle is 28 days)

  2. Dose Expansion - Platelet count

    Part 2: Proportion of participants achieving a platelet count of 450 × 10⁹/L or lower.

    Time frame: Up to 2 years

Secondary outcomes

  1. Dose Escalation - Incidence of Treatment-Emergent Adverse Events (TEAEs)

    Incidence and severity of treatment-emergent adverse events and clinically significant changes in laboratory tests, vital signs, electrocardiograms, and physical examinations.

    Time frame: From first dose up to 2 years

  2. Pharmacokinetic measures

    Pharmacokinetic measures of JBI-802 and its metabolites, including maximum concentration, time to maximum concentration, and area under the concentration-time curve. Units: ng/mL

    Time frame: From Cycle 1 Day 1 up to Cycle 7 Day 1 (each cycle is 28 days)

  3. Measures of clinical activity

    3\. Measures of clinical activity, including platelet control, white blood cell normalization, hematocrit control in participants with ET/PV, and duration of platelet control.

    Time frame: From first dose up to 2 years

07

Study locations

7 of 7 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Oct 2024 (actual). Primary completion is estimated for Jan 2031, 75 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 17, 2026: primary completion Jun 2028 → Jan 2031 and completion Sep 2028 → Jan 2031.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 11, 2025
First posted
May 28, 2026
StartActual
Oct 21, 2024
Primary completionEst.
Jan 30, 2031was Jun 2028
CompletionEst.
Jan 30, 2031was Sep 2028
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jun 15, 2028→Jan 30, 2031
Nov 17, 2026
Study completion
Sep 15, 2028→Jan 30, 2031
Nov 17, 2026
Enrollment
30→70
Nov 17, 2026
Eligibility
Criteria largely rewritten (61 changes)
What changed in the criteria
Inclusion criteria
  • Removed- Male or female subjects aged ≥18 years at the time of screening visit.
  • RemovedFor Dose Escalation Phase:
  • RemovedSubjects diagnosed with any one of the following:
  • RemovedSubject with diagnosis of Essential Thrombocythemia (ET) per World Health Organization (WHO) diagnostic criteria for myeloproliferative neoplasms .
  • RemovedSubject requires treatment in order to lower platelet count based on subject age over 60 or history of thrombosis.
  • RemovedSubject with Morphologically confirmed diagnosis of MDS/MPN neoplasms, excluding Juvenile Myelomonocytic Leukaemia (JMML), CMML and aCML (Atypical Chronic Myeloid Leukaemia), in accordance with WHO 2016 revised criteria, that is relapsed and/or refractory or intolerant to standard of care and that, in the opinion of the Investigator, subjects who have no available therapies known to provide clinical benefits.
  • RemovedSubject with Myelodysplastic/myeloproliferative neoplasm, (unclassifiable (MDS/MPN-UC) and MDS/MPN-RS-T).
  • RemovedFor Dose Expansion Phase
  • RemovedSubjects diagnosed with any one of the following:
  • RemovedSubject with diagnosis of Essential Thrombocythemia (ET) per WHO diagnostic criteria for myeloproliferative neoplasms which requires treatment in order to lower platelet count based on subject age over 60 or history of thrombosis.
  • RemovedSubject with diagnosis of Polycythemia Vera (PV) per WHO diagnostic criteria that is relapsed and/or refractory or intolerant to standard of care and that, in the opinion of the Investigator, subjects who have no available therapies known to provide clinical benefits Subject with morphologically confirmed diagnosis of pre-fibrotic myelofibrosis (MF) subject in accordance with the WHO 2016 revised criteria, that is relapsed, intolerant, and/or refractory and that, in the opinion of the Investigator, subjects who have no available therapies known to provide clinical benefits. (Refer Appendix II)
  • RemovedMDS/MPN (MDS/MPN-RS-T, MDS/MPN unclassifiable and CMML subjects providing the marrow blast count is ≤5%.). 2. Subject must have disease that failed at least one standard therapy or being intolerant to standard of care. 3. Subject must have discontinued immediate prior therapy at least 1 week (4 weeks for interferon) prior to study drug administration. 4. Subject with screening laboratory values:
  • RemovedHb ≥ 9 g/dL, if subject is transfused to meet this criterion, transfusion must be completed ≥ 14 days prior to first dose.
  • RemovedAbsolute neutrophil count ≥ 1500 × 109/L
  • RemovedAbsolute neutrophil count ≥ 1000 × 109/L, if significant marrow infiltration
  • RemovedPlatelet count ≥ 450 × 109/L for dose finding
  • RemovedPlatelet count ≥ 100 × 109/L for expansion cohort at RP2D, if subject is transfused to meet this criterion, transfusion must be completed ≥14 days prior to first dose
  • RemovedTotal bilirubin ≤ 1.5 × ULN. Subjects with Gilbert's syndrome may be enrolled with up to 3.0 × ULN
  • RemovedAspartate transaminase (AST) and Alanine transaminase (ALT) ≤ 2.5 × ULN (unless liver metastases are present then up to 5 × ULN is allowed)
  • RemovedCalculated creatinine clearance (CrCL) ≥ 30 mL/min (Cockcroft- Gault formula) (Refer Appendix IV)
  • RemovedProthrombin Time (PT) or Activated Partial Thromboplastin Time (aPTT) ≤ 1.5 × ULN, if subject is not anticoagulated (Note: If subject is on anticoagulants, the subject must be on a stable dose for at least 2 weeks prior to screening) 5. Subject with resolution of any clinically significant toxic effects of prior therapy to Grade 0 or 1 according to the NCI CTCAE, Version 5.0 (exception of alopecia and Grade 2 peripheral neuropathy, chronic Grade 2 endocrinopathies as a result of prior immunotherapy). (Refer Appendix VII) 6. Subject with Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2. (Refer Appendix III) 7. Subject able to swallow oral medication. 8. Subject who has willing and able to give informed consent and comply with protocol requirements for the duration of the study. 9. Subject who is willing to undergo bone marrow biopsy with aspiration and tissue collection for disease assessment and correlative studies during screening and periodically throughout the study. 10. Subject with willingness to use contraception by a method that is deemed effective by the Investigator by both males and female of childbearing potential (post-menopausal women must have been amenorrhoeal for at least 12 months to be considered of non-childbearing potential (i.e., surgically sterilised [hysterectomy, bilateral salpingectomy, bilateral oophorectomy at least 6 weeks before the screening visit] or postmenopausal [where postmenopausal is defined as no menses for 12 months wi…
  • AddedAge 18 years or older with ET or PV and persistent thrombocytosis (platelet count at least 450 × 10⁹/L).
  • AddedAt least one recognized risk factor for thrombosis, such as prior thrombosis, age 60 years or older, or another investigator-determined risk factor.
  • AddedDisease that has not responded adequately to, or cannot tolerate, at least one standard cytoreductive therapy.
  • AddedAdequate blood counts, liver and kidney function, and coagulation results as defined in the protocol; ECOG performance status of 0 to 2.
  • AddedAble to swallow oral medication, provide informed consent, follow study requirements, and undergo required bone marrow assessments.
  • AddedParticipants of reproductive potential must meet protocol contraception requirements during treatment and for 90 days after the last dose.
Exclusion criteria
  • Removed1. Subject who is treated with systemic anticancer therapy or biological therapy or an investigational agent within 2 weeks or 5 half-lives, whichever is shorter, prior to start of study drug treatment.
  • RemovedFor MF subject who come off JAK2 antagonists or hydroxyurea, shorter washout is permitted as these subject progress quickly after treatment discontinuation and remain eligible (steroids must be stop at least 7 day before start of study drug treatment)
  • RemovedSubject who is in need of immediate cytoreduction should be excluded 2. Subject who has undergone autologous/allogeneic Haematopoietic Stem Cell Transplantation (HSCT) therapy within 60 days of the first dose of study drug, or subject on immunosuppressive therapy post-HSCT at the time of screening, or currently with clinically significant Graft-Versus- Host Disease (GVHD) as per treating physician (subjects in relapse after allogeneic transplantation must be off treatment with systemic immunosuppressive agents for at least 4 weeks prior to screening.
  • Removed3. Subject with major surgery less than or equal to 21 days prior to starting study drug or has not recovered from adverse effects of such procedure.
  • Removed4. Subject who underwent surgery (e.g., stomach bypass) or medical condition that might significantly affect absorption of medicines.
  • Removed5. Subject who underwent radiotherapy within 2 weeks prior to start of study drug treatment (palliative radiation or stereotactic radiosurgery within 7 days prior to start of study treatment). Subjects must have recovered from all radiotherapy-related toxicities.
  • Removed6. Subject with known malignant central nervous system disease other than neurologically stable, treated brain metastases- defined as metastasis having no evidence of progression or hemorrhage for at least 4 weeks after treatment (including brain radiotherapy). Must be off any systemic corticosteroids for the treatment of symptomatic brain metastases for at least 14 days prior to enrollment.
  • Removed7. Subject with severe or unstable medical condition, such as congestive heart failure ischemic heart disease, uncontrolled hypertension, uncontrolled diabetes mellitus, psychiatric condition, as well as an uncontrolled cardiac arrhythmia requiring medication ( less than or equal to Grade 2, according to NCI CTCAE Version 5), myocardial infarction within 6 months prior to starting study treatment, or any other significant or unstable concurrent cardiac illness.
  • Removed8. Subject with congenital long QT syndrome or corrected QT interval by Fridericia (QTcF interval) greater than 450 msec for males and greater than 470 msec for females at screening.
  • Removed9. Subject with history of other previous or concurrent cancer that would interfere with the determination of safety or efficacy assessments with the exception:
  • RemovedPatient with previous cancers can be included to the study provided they are in remission at the time of screening and enrolment.
  • RemovedPatient with localized skin cancer can also be included for screening and enrollment.
  • Removed10. Subject with live vaccines within 30 days prior to the first dose of JBI-802.

…and 21 more changes, on the record history on ClinicalTrials.gov ↗

Nov 17, 2026
Primary outcomes
1 edited, 4 removed, 1 description edited
What changed in the outcomes
  • EditedDose Expansion - Platelet Count ≤400 ×10⁹/L Without Thromboembolic EventscountTime frame: Up to 2 years
  • RemovedDose Expansion - Overall Response Rate (ORR)Time frame: Up to 2 years
  • RemovedDose Expansion - Complete Remission (CR) RateTime frame: Up to 2 years
  • RemovedDose Expansion - Progression-Free Survival (PFS)Time frame: At 6 months and up to approximately 2 years
  • RemovedDose Expansion - Overall Survival (OS)Time frame: Up to 2 years
  • DescriptionDose Escalation - Incidence of Dose-Limiting Toxicities (DLTs): how it is measured was reworded
Nov 17, 2026
Secondary outcomes
2 added, 7 removed, 1 description edited
What changed in the outcomes
  • AddedPharmacokinetic measuresTime frame: From Cycle 1 Day 1 up to Cycle 7 Day 1 (each cycle is 28 days)
  • AddedMeasures of clinical activityTime frame: From first dose up to 2 years
  • RemovedMaximum Plasma Concentration (Cmax) of JBI-802Time frame: From Cycle 1 Day 1 up to Cycle 3 Day 1 (each cycle is 28 days)
  • RemovedArea Under the Plasma Concentration-Time Curve (AUC0-t) of JBI-802Time frame: From Cycle 1 Day 1 up to Cycle 3 Day 1 (each cycle is 28 days)
  • RemovedTime to Maximum Plasma Concentration (Tmax) of JBI-802Time frame: From Cycle 1 Day 1 up to Cycle 3 Day 1 (each cycle is 28 days)
  • RemovedOverall Response Rate (ORR)Time frame: Up to 2 years
  • RemovedDuration of Response (DOR)Time frame: Up to 2 years
  • RemovedPlatelet Count ≤400 ×10⁹/L Without Thromboembolic EventsTime frame: Up to 2 years
  • RemovedDose Expansion - Change From Baseline in MPN-SAF Total Symptom Score (TSS)Time frame: Up to 2 years
  • DescriptionDose Escalation - Incidence of Treatment-Emergent Adverse Events (TEAEs): how it is measured was reworded
Nov 17, 2026
Contact
Study contact changed: m•••@jubl.com · •••4319→V•••@jubilanttx.com · •••5112. See the current contact
Nov 17, 2026
Title
Phase 1/ Phase 2 Study to Assess Safety and Preliminary Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative NeoplasmsEssential Thrombocythemia (MPNET) and Myelodysplastic/Myeloproliferative NeoplasmsPolycythemia Vera (MDS/MPNPV) With Thrombocytosis
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Primary completion Jun 15, 2028→Jan 30, 2031
    Study completion Sep 15, 2028→Jan 30, 2031
    Enrollment 30→70
    Eligibility Criteria largely rewritten (61 changes)
    What changed in the criteria
    Inclusion criteria
    • Removed- Male or female subjects aged ≥18 years at the time of screening visit.
    • RemovedFor Dose Escalation Phase:
    • RemovedSubjects diagnosed with any one of the following:
    • RemovedSubject with diagnosis of Essential Thrombocythemia (ET) per World Health Organization (WHO) diagnostic criteria for myeloproliferative neoplasms .
    • RemovedSubject requires treatment in order to lower platelet count based on subject age over 60 or history of thrombosis.
    • RemovedSubject with Morphologically confirmed diagnosis of MDS/MPN neoplasms, excluding Juvenile Myelomonocytic Leukaemia (JMML), CMML and aCML (Atypical Chronic Myeloid Leukaemia), in accordance with WHO 2016 revised criteria, that is relapsed and/or refractory or intolerant to standard of care and that, in the opinion of the Investigator, subjects who have no available therapies known to provide clinical benefits.
    • RemovedSubject with Myelodysplastic/myeloproliferative neoplasm, (unclassifiable (MDS/MPN-UC) and MDS/MPN-RS-T).
    • RemovedFor Dose Expansion Phase
    • RemovedSubjects diagnosed with any one of the following:
    • RemovedSubject with diagnosis of Essential Thrombocythemia (ET) per WHO diagnostic criteria for myeloproliferative neoplasms which requires treatment in order to lower platelet count based on subject age over 60 or history of thrombosis.
    • RemovedSubject with diagnosis of Polycythemia Vera (PV) per WHO diagnostic criteria that is relapsed and/or refractory or intolerant to standard of care and that, in the opinion of the Investigator, subjects who have no available therapies known to provide clinical benefits Subject with morphologically confirmed diagnosis of pre-fibrotic myelofibrosis (MF) subject in accordance with the WHO 2016 revised criteria, that is relapsed, intolerant, and/or refractory and that, in the opinion of the Investigator, subjects who have no available therapies known to provide clinical benefits. (Refer Appendix II)
    • RemovedMDS/MPN (MDS/MPN-RS-T, MDS/MPN unclassifiable and CMML subjects providing the marrow blast count is ≤5%.). 2. Subject must have disease that failed at least one standard therapy or being intolerant to standard of care. 3. Subject must have discontinued immediate prior therapy at least 1 week (4 weeks for interferon) prior to study drug administration. 4. Subject with screening laboratory values:
    • RemovedHb ≥ 9 g/dL, if subject is transfused to meet this criterion, transfusion must be completed ≥ 14 days prior to first dose.
    • RemovedAbsolute neutrophil count ≥ 1500 × 109/L
    • RemovedAbsolute neutrophil count ≥ 1000 × 109/L, if significant marrow infiltration
    • RemovedPlatelet count ≥ 450 × 109/L for dose finding
    • RemovedPlatelet count ≥ 100 × 109/L for expansion cohort at RP2D, if subject is transfused to meet this criterion, transfusion must be completed ≥14 days prior to first dose
    • RemovedTotal bilirubin ≤ 1.5 × ULN. Subjects with Gilbert's syndrome may be enrolled with up to 3.0 × ULN
    • RemovedAspartate transaminase (AST) and Alanine transaminase (ALT) ≤ 2.5 × ULN (unless liver metastases are present then up to 5 × ULN is allowed)
    • RemovedCalculated creatinine clearance (CrCL) ≥ 30 mL/min (Cockcroft- Gault formula) (Refer Appendix IV)
    • RemovedProthrombin Time (PT) or Activated Partial Thromboplastin Time (aPTT) ≤ 1.5 × ULN, if subject is not anticoagulated (Note: If subject is on anticoagulants, the subject must be on a stable dose for at least 2 weeks prior to screening) 5. Subject with resolution of any clinically significant toxic effects of prior therapy to Grade 0 or 1 according to the NCI CTCAE, Version 5.0 (exception of alopecia and Grade 2 peripheral neuropathy, chronic Grade 2 endocrinopathies as a result of prior immunotherapy). (Refer Appendix VII) 6. Subject with Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2. (Refer Appendix III) 7. Subject able to swallow oral medication. 8. Subject who has willing and able to give informed consent and comply with protocol requirements for the duration of the study. 9. Subject who is willing to undergo bone marrow biopsy with aspiration and tissue collection for disease assessment and correlative studies during screening and periodically throughout the study. 10. Subject with willingness to use contraception by a method that is deemed effective by the Investigator by both males and female of childbearing potential (post-menopausal women must have been amenorrhoeal for at least 12 months to be considered of non-childbearing potential (i.e., surgically sterilised [hysterectomy, bilateral salpingectomy, bilateral oophorectomy at least 6 weeks before the screening visit] or postmenopausal [where postmenopausal is defined as no menses for 12 months wi…
    • AddedAge 18 years or older with ET or PV and persistent thrombocytosis (platelet count at least 450 × 10⁹/L).
    • AddedAt least one recognized risk factor for thrombosis, such as prior thrombosis, age 60 years or older, or another investigator-determined risk factor.
    • AddedDisease that has not responded adequately to, or cannot tolerate, at least one standard cytoreductive therapy.
    • AddedAdequate blood counts, liver and kidney function, and coagulation results as defined in the protocol; ECOG performance status of 0 to 2.
    • AddedAble to swallow oral medication, provide informed consent, follow study requirements, and undergo required bone marrow assessments.
    • AddedParticipants of reproductive potential must meet protocol contraception requirements during treatment and for 90 days after the last dose.
    Exclusion criteria
    • Removed1. Subject who is treated with systemic anticancer therapy or biological therapy or an investigational agent within 2 weeks or 5 half-lives, whichever is shorter, prior to start of study drug treatment.
    • RemovedFor MF subject who come off JAK2 antagonists or hydroxyurea, shorter washout is permitted as these subject progress quickly after treatment discontinuation and remain eligible (steroids must be stop at least 7 day before start of study drug treatment)
    • RemovedSubject who is in need of immediate cytoreduction should be excluded 2. Subject who has undergone autologous/allogeneic Haematopoietic Stem Cell Transplantation (HSCT) therapy within 60 days of the first dose of study drug, or subject on immunosuppressive therapy post-HSCT at the time of screening, or currently with clinically significant Graft-Versus- Host Disease (GVHD) as per treating physician (subjects in relapse after allogeneic transplantation must be off treatment with systemic immunosuppressive agents for at least 4 weeks prior to screening.
    • Removed3. Subject with major surgery less than or equal to 21 days prior to starting study drug or has not recovered from adverse effects of such procedure.
    • Removed4. Subject who underwent surgery (e.g., stomach bypass) or medical condition that might significantly affect absorption of medicines.
    • Removed5. Subject who underwent radiotherapy within 2 weeks prior to start of study drug treatment (palliative radiation or stereotactic radiosurgery within 7 days prior to start of study treatment). Subjects must have recovered from all radiotherapy-related toxicities.
    • Removed6. Subject with known malignant central nervous system disease other than neurologically stable, treated brain metastases- defined as metastasis having no evidence of progression or hemorrhage for at least 4 weeks after treatment (including brain radiotherapy). Must be off any systemic corticosteroids for the treatment of symptomatic brain metastases for at least 14 days prior to enrollment.
    • Removed7. Subject with severe or unstable medical condition, such as congestive heart failure ischemic heart disease, uncontrolled hypertension, uncontrolled diabetes mellitus, psychiatric condition, as well as an uncontrolled cardiac arrhythmia requiring medication ( less than or equal to Grade 2, according to NCI CTCAE Version 5), myocardial infarction within 6 months prior to starting study treatment, or any other significant or unstable concurrent cardiac illness.
    • Removed8. Subject with congenital long QT syndrome or corrected QT interval by Fridericia (QTcF interval) greater than 450 msec for males and greater than 470 msec for females at screening.
    • Removed9. Subject with history of other previous or concurrent cancer that would interfere with the determination of safety or efficacy assessments with the exception:
    • RemovedPatient with previous cancers can be included to the study provided they are in remission at the time of screening and enrolment.
    • RemovedPatient with localized skin cancer can also be included for screening and enrollment.
    • Removed10. Subject with live vaccines within 30 days prior to the first dose of JBI-802.

    …and 21 more changes, on the record history on ClinicalTrials.gov ↗

    Primary outcomes 1 edited, 4 removed, 1 description edited
    What changed in the outcomes
    • EditedDose Expansion - Platelet Count ≤400 ×10⁹/L Without Thromboembolic EventscountTime frame: Up to 2 years
    • RemovedDose Expansion - Overall Response Rate (ORR)Time frame: Up to 2 years
    • RemovedDose Expansion - Complete Remission (CR) RateTime frame: Up to 2 years
    • RemovedDose Expansion - Progression-Free Survival (PFS)Time frame: At 6 months and up to approximately 2 years
    • RemovedDose Expansion - Overall Survival (OS)Time frame: Up to 2 years
    • DescriptionDose Escalation - Incidence of Dose-Limiting Toxicities (DLTs): how it is measured was reworded
    Secondary outcomes 2 added, 7 removed, 1 description edited
    What changed in the outcomes
    • AddedPharmacokinetic measuresTime frame: From Cycle 1 Day 1 up to Cycle 7 Day 1 (each cycle is 28 days)
    • AddedMeasures of clinical activityTime frame: From first dose up to 2 years
    • RemovedMaximum Plasma Concentration (Cmax) of JBI-802Time frame: From Cycle 1 Day 1 up to Cycle 3 Day 1 (each cycle is 28 days)
    • RemovedArea Under the Plasma Concentration-Time Curve (AUC0-t) of JBI-802Time frame: From Cycle 1 Day 1 up to Cycle 3 Day 1 (each cycle is 28 days)
    • RemovedTime to Maximum Plasma Concentration (Tmax) of JBI-802Time frame: From Cycle 1 Day 1 up to Cycle 3 Day 1 (each cycle is 28 days)
    • RemovedOverall Response Rate (ORR)Time frame: Up to 2 years
    • RemovedDuration of Response (DOR)Time frame: Up to 2 years
    • RemovedPlatelet Count ≤400 ×10⁹/L Without Thromboembolic EventsTime frame: Up to 2 years
    • RemovedDose Expansion - Change From Baseline in MPN-SAF Total Symptom Score (TSS)Time frame: Up to 2 years
    • DescriptionDose Escalation - Incidence of Treatment-Emergent Adverse Events (TEAEs): how it is measured was reworded
    Contact Study contact changed: m•••@jubl.com · •••4319→V•••@jubilanttx.com · •••5112. See the current contact
    Title Phase 1/ Phase 2 Study to Assess Safety and Preliminary Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative NeoplasmsEssential Thrombocythemia (MPNET) and Myelodysplastic/Myeloproliferative NeoplasmsPolycythemia Vera (MDS/MPNPV) With Thrombocytosis
    + 5 other changes: index terms, verification date, oversight details, description and conditions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07612280
Lead sponsor
Jubilant Therapeutics Inc.
Responsible party
Sponsor
First posted
May 28, 2026
Start date
Oct 21, 2024
Primary completion
Jan 30, 2031 (estimated)
Completion
Jan 30, 2031 (estimated)
Last update
Nov 17, 2026

Study contacts

Hagop Youssoufian
Contact
V-Hagop.Youssoufian@jubilanttx.com
+1 617-631-5112

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: JBI-802

Start the discussion